CSJ117

Phase 2Small molecule

Novartis

CSJ117 is one of 36 small molecule programs targeting Atopic Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic AsthmaActive, not recruiting

AsthmaActive, not recruiting

Atopic AsthmaPhase 1

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 3

Spiriva

Boehringer Ingelheim

Preclinical

8 4

Atrovent

Boehringer Ingelheim

Preclinical

5 5

CSJ117

Novartis

Phase 2

2 6

Symbicort

AstraZeneca

Preclinical

6 7

Atrovent

Boehringer Ingelheim

Preclinical

2 8

Aciphex

Akero Therapeutics

Preclinical

2 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma2 trials

Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

Terminated· Novartis logo

Novartis·Phase 2·NCT04946318·136 enrolled

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

Terminated· Novartis logo

Novartis·Phase 2·NCT04410523·335 enrolled

Atopic Asthma1 trial

A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma

Completed· Novartis logo

Novartis·Phase 1·NCT03138811·28 enrolled

COPD1 trial

Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

Completed· Novartis logo

Novartis·Phase 2·NCT04882124·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CSJ117. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CSJ117 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CSJ117. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

CSJ117

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma2 trials

Atopic Asthma1 trial

COPD1 trial

References

Drug Info

Quick Facts

Related News